M1FG
RCUS icon

Mach-1 Financial Group’s Arcus Biosciences RCUS Stock Holding History

Mach-1 Financial Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,314
Closed -$483K – 184
2023
Q4 		$483K Buy
25,314
+2,540
+11% +$40.6K 0.18% 116
2023
Q3 		$409K Buy
+22,774
New +$458K 0.17% 160

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mach-1 Financial Group's RCUS Position: Q1 2024 in Review

Mach-1 Financial Group sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 25,314 shares — an estimated $483K sold.

Mach-1 Financial Group first reported a position in RCUS in Q3 2023 and held it in 2 quarters. The position peaked at $483K in Q4 2023. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • Mach-1 Financial Group reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
  • Mach-1 Financial Group sold 25,314 Arcus Biosciences shares in Q1 2024, an estimated $483K.
  • Mach-1 Financial Group first reported a position in Arcus Biosciences in Q3 2023 and held it in 2 quarters.
  • Mach-1 Financial Group's Arcus Biosciences position peaked at $483K in Q4 2023.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on Mach-1 Financial Group's 13F filing for Q1 2024, filed 10 May 2024.